InSilico Medicine and Ascend Biopharmaceuticals reach a strategic partnership.

and Shanghai Angsheng Biomedical Technology Co., Ltd. signed a strategic cooperation agreement. Both parties will focus on the development of AI-driven precision therapies for stem cells and their derivatives. By jointly building an extracellular vesicle multi-omics database and using AI to deeply explore the "extracellular vesicles-disease" association network, they aim to tackle the industry's challenges in extracellular vesicle component analysis and target matching. This will accelerate the transformation of stem cell extracellular vesicle therapy from basic research to clinical application.